FDA Approves AbbVie's JUVMO, First Selective D1/D5 Agonist for Parkinson's, With US Launch Set for October

ABBV won U.S. Food and Drug Administration approval on September 28, 2026 for JUVMO (tavapadon), the first and only selective D1/D5 dopamine receptor agonist for adults with Parkinson's disease . The once-daily tablet can be taken alone or alongside levodopa. Approval rests on the Phase 3 TEMPO program: TEMPO-1 and TEMPO-2 studied early-stage patients not on levodopa, and TEMPO-3 tested the drug as an add-on for patients with motor fluctuations. The most common side effects included nausea, headache, change in taste, fatigue, vomiting, dry mouth and anxiety. AbbVie expects the drug to reach U.S. patients in October.

The mechanism is what sets JUVMO apart. Existing dopamine agonists mainly target D2/D3 receptors, and tavapadon's selectivity for D1/D5 is intended to control motor symptoms through a different pathway. The approval also validates AbbVie's $8.7 billion takeover of Cerevel Therapeutics, where tavapadon originated. It landed in a busy regulatory week that also brought clearances for Lilly's Olumiant, Mirum and Incyte.

Analysts see a sizable opportunity: one widely circulated note argued the pill could become a billion-dollar drug, and William Blair models sales of $1.4 billion in 2040. AbbVie frames JUVMO as part of a Parkinson's franchise it believes could generate $5 billion a year at peak. The near-term picture is more measured, since management has signaled a slow launch. Watch pricing, payer formulary placement and early prescription trends over the first few quarters, which will show whether the D1/D5 differentiation converts into share against established Parkinson's therapies.